The role of AI in predicting stem cell donor availability

Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

The role of AI in predicting stem cell donor availability

The success of unrelated donor stem cell transplants depends on not only finding genetically matched donors but also donor availability. On average, 50% of potential donors in the National Marrow Donor Program database are unavailable for a variety of reasons after initially matching a patient, with significant variations in availability among subgroups (e.g., by race or age). Several studies have established univariate donor characteristics associated with availability. Individual consideration of each applicable characteristic is laborious, and extrapolating group averages to the individual donor level tends to be highly inaccurate. In the current environment with enhanced donor data collection, there are better ways to make estimates of individual donor availability. It's about donor quality vs. quantity.

The presenter and panel will discuss how bioinformatics, world-class partners, and technology are making the search better. Specifically, how a ground-breaking AI-based approach like the Donor Readiness Score (DRS) can predict the availability of every registered donor and evaluate the predictive power during donor selection to reduce the time to transplant. Essentially, this approach changes how the industry considers donors, from quantity to quality.

Attend this webinar to learn how to:

Predict an individual donor's availability to move forward to donation
Match these predictions to provide a cumulative probability of search productivity and the likelihood of having an 8/8, 7/8, 10/10, or 9/10 matched available donor
Automatically take into account multiple donor features like age, gender, geographical location, race, ethnicity, and many more
Enhance your accuracy and effectiveness in producing a candidate donor pool for cell/source selection that would be available when called to donate
Improve multiple stages of the cellular therapy experience

Abeer Madbouly

Principal Bioinformatics Scientist at NMDP BioTherapies

Abeer Madbouly has over 15 years of experience in bioinformatics. Her role involves improving the donor/patient tissue matching process by developing better validation methods, more innovative matching, better collection of donor and recipient race/ethnicity/ancestry information and diversified population genetics analyses. She investigates multiple gene systems with the goal of improving post-transplant event-free survival.

Dr Madbouly joined the NMDP Bioinformatics team in 2010. She earned a Doctor of Philosophy in Electrical and Computer Engineering from the University of Miami, Coral Gables, FL. She currently serves as adjunct assistant professor at the University of Minnesota, Bioinformatics and Computational Biology program and the Chair of the Science and Technology Initiatives Committee at the American Society of Histocompatibility and Immunogenetics.

Jennifer Mcatee

Lead Donor Search & Procurement, Blood & Marrow Transplantation and Cancer Cellular Therapy Program at Stanford Health Care

Jennifer is the lead donor search and procurement coordinator within the Blood and Marrow Transplant and Cellular Therapy Program at Stanford Health Care. Her experience includes aiding and improving in the identification of HLA-genetically matched donors, advancing the coordination of allogeneic hematopoietic transplantation by evidenced based research, to decrease the timeline to transplant to help improve curative outcomes and reduce complexities for the clinical team and patients.

Brian Shaffer

Associate Member at Memorial Sloan Kettering Cancer Center

Dr Brian Shaffer is an assisting attending physician at Memorial Sloan Kettering Cancer Center. He is a clinician scientist in the field of cellular therapy and bone marrow transplantation, with clinical expertise in the management of myeloid neoplasia and bone marrow failure syndromes, including stem cell transplantation.

He received his MD from Eastern Virginia Medical School in 2005, and holds a Master of Science, specialising in epidemiology, from Weill Cornell Graduate School of Medical Sciences.

Martin Maiers

Vice President, Research at NMDP BioTherapies

Martin Maiers, MS, is the Vice President of Research at NMDP BioTherapies. He and his team develop software and analytical methods used to predict factors that can impact outcomes for patients who receive an allogeneic cell therapy. Maiers has worked with many allogeneic cell therapy developers in both the early stages of therapy development and as they move through clinical trials.